ClinicalTrials.gg

Program

garsorasib

Also written as “D-1553”, “IN10018 in combination with D-1553” and “D-1553 Tablet”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Furthest: phase 3, since Sep 27, 20208 company-led studies, 4 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InventisBio62 open or runningphase 2since Sep 27, 2020Sep 27, 2020Dec 31, 2027phase 2 · NCT05379946
InxMed (Shanghai)11 open or runningphase 3since Aug 29, 2025Aug 29, 2025Sep 2028phase 3 · NCT07174908
Sino Biopharmaceutical11 open or runningphase 3since Mar 3, 2024Mar 3, 2024none ahead

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2020First study: phase 2 study in Solid Tumor, AdultNew to InventisBioInventisBio · NCT04585035 · 180 enrolled · United States, Australia, Korea, Republic of and more
  2. May 13, 20222 phase 2 studiesInventisBio · NCT05383898, NCT05379946
  3. Aug 5, 2022Phase 2 study in NSCLCInventisBio · NCT05492045 · 22 enrolled · China
  4. Oct 17, 2023Phase 1 study in Healthy MaleInventisBio · NCT06105255 · 45 enrolled · China
  5. Nov 27, 2023Phase 1 study in Mass Balance StudyInventisBio · NCT06233916 · 8 enrolled · China
  6. Mar 3, 2024Sino Biopharmaceutical's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06300177 · 522 planned · China
  7. Aug 29, 2025InxMed (Shanghai)'s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to InxMed (Shanghai)InxMed (Shanghai) · NCT07174908 · 400 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Solid TumorInventisBio · NCT05379946
  2. Sep 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungInxMed (Shanghai) · NCT07174908

TargetBeta

KRAS →read by rule
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07174908Carcinoma, Non-Small-Cell Lung · China3RecruitingInxMed (Shanghai)Sep 2028400
NCT06300177Carcinoma, Non-Small-Cell Lung · China3RecruitingSino BiopharmaceuticalOct 2026522
NCT06233916Mass Balance Study · China1CompletedInventisBioJan 3, 20248
NCT06105255Healthy Male · China1CompletedInventisBioFeb 2, 202445
NCT05492045NSCLC · China2TerminatedInventisBioJun 14, 202422
NCT05383898NSCLC · China2CompletedInventisBioNov 17, 2023225
NCT05379946Solid Tumor · China2Active, not recruitingInventisBioDec 31, 202792
NCT04585035Solid Tumor, Adult · United States, Australia, Korea, Republic of and more2Active, not recruitingInventisBioApr 30, 2024180

How it is read

Names in the registry

  • “D-1553”, 5 entries
  • “IN10018 in combination with D-1553”, 1 entry
  • “D-1553 Tablet”, 1 entry
  • “[14C] D-1553”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.